Tower Research Capital LLC TRC Grows Stock Position in MeiraGTx Holdings plc (NASDAQ:MGTX)

Tower Research Capital LLC TRC increased its position in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 91.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,286 shares of the company’s stock after buying an additional 2,045 shares during the quarter. Tower Research Capital LLC TRC’s holdings in MeiraGTx were worth $30,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its position in shares of MeiraGTx by 383.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,354 shares of the company’s stock valued at $52,000 after buying an additional 5,832 shares during the period. SG Americas Securities LLC purchased a new stake in MeiraGTx in the third quarter valued at approximately $60,000. Letko Brosseau & Associates Inc. purchased a new stake in MeiraGTx in the third quarter valued at approximately $111,000. Finally, Jump Financial LLC purchased a new stake in MeiraGTx in the fourth quarter valued at approximately $372,000. Hedge funds and other institutional investors own 67.48% of the company’s stock.

MeiraGTx Stock Up 0.2 %

Shares of MeiraGTx stock traded up $0.01 during trading hours on Friday, reaching $5.00. 78,548 shares of the company were exchanged, compared to its average volume of 138,019. MeiraGTx Holdings plc has a 1 year low of $3.49 and a 1 year high of $8.35. The stock’s fifty day moving average is $5.73 and its 200 day moving average is $5.67. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.38 and a current ratio of 2.38. The firm has a market cap of $321.54 million, a PE ratio of -3.40 and a beta of 1.31.

MeiraGTx (NASDAQ:MGTX) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). MeiraGTx had a negative return on equity of 114.33% and a negative net margin of 599.47%. The company had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $10.13 million. As a group, equities research analysts forecast that MeiraGTx Holdings plc will post -1.4 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on MGTX shares. Royal Bank of Canada reissued an “outperform” rating and issued a $11.00 target price on shares of MeiraGTx in a research report on Friday, March 15th. TheStreet raised MeiraGTx from a “d” rating to a “c-” rating in a research report on Friday, March 15th.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.